** Retail pharmacy franchisor Sigma Healthcare's SIG.AX shares are considered overvalued by Morningstar despite in-line earnings
** Full-year underlying EBIT growth more than doubled to A$68 mln was within co's forecast - Brokerage
** Adds revenue surged 46% to A$4.8 bln, mainly due to increased prescription volumes supplied to Chemist Warehouse $(CW)$
** However, gross margins in H2 shrank more than anticipated to 5.4% due to lower-margin prescription medicine sales - Morningstar
** Brokerage adds that SIG's market cap is similar to grocer Woolworths WOW.AX at over A$34 bln, suggesting a P/E ratio of 42 for fiscal 2029, including earnings from CW indicating overvaluation
** Morningstar maintains A$1.65/share fair value estimate
** Stock up 11.1% YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。